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The emergence and spread of multidrug-resistant 
(MDR) and extensively drug-resistant (XDR) tuberculosis 
(TB) has raised public health concern about global control 
of TB. To estimate the transmission dynamics of MDR and 
XDR TB, we conducted a DNA ﬁ  ngerprinting analysis of 
55 MDR/XDR Mycobacterium tuberculosis strains isolated 
from TB patients throughout Japan in 2002. Twenty-one 
(38%) of the strains were classiﬁ   ed into 9 clusters with 
geographic links, which suggests that community trans-
mission of MDR/XDR TB is ongoing. Furthermore, the 
XDR  M. tuberculosis strains were more likely than the 
non–XDR MDR strains to be clustered (71% vs. 24%; p = 
0.003), suggesting that transmission plays a critical role in 
the new incidence of XDR TB. These ﬁ  ndings highlight the 
difﬁ  culty of preventing community transmission of XDR TB 
by conventional TB control programs and indicate an ur-
gent need for a more appropriate strategy to contain highly 
developed drug-resistant TB.
T
he epidemic of drug-resistant tuberculosis (TB) has 
raised public health concern about the global control 
of TB. The World Health Organization estimated that 0.5 
million cases of multidrug-resistant TB (MDR TB) (i.e., 
Mycobacterium tuberculosis resistant to >2 of the most po-
tent TB drugs, rifampin and isoniazid) occurred in 2007 
(1). Some countries have extraordinarily high rates of this 
disease, but the problem is universal, and the extent varies 
from 1 country to another.
Another recent alarming issue is the emergence of ex-
tensively drug-resistant TB (XDR TB) (i.e., M. tuberculo-
sis with MDR plus resistance to any ﬂ  uoroquinolone and 
>1 injectable drug, thus posing even greater management 
challenges than MDR TB alone). The treatment outcome 
of XDR TB is worse than that of simple MDR TB, and 
the death rate is particularly high among HIV-infected pa-
tients (2). Also, because XDR TB is much more expensive 
to manage in terms of prolonged medication and prolonged 
period of infectivity to other persons (3), it has the poten-
tial to exhaust human and ﬁ  nancial resources of the public 
health system for TB control. Although this new life-threat-
ening disease had been reported from 49 countries as of 
June 2008 (4), its transmissibility among immunocompe-
tent persons is not well known (5).
In Japan, TB remains a major infectious disease; in 
2008, a total of 19.4 cases/100,000 population were re-
ported (6), and Japan is generally classiﬁ  ed as a country 
with intermediate TB incidence. According to the most re-
cent nationwide drug-resistance survey, the prevalence of 
MDR TB and XDR TB were 1.9% and 0.5%, respectively 
(7). Approximately one third of MDR and XDR (MDR/
XDR) M. tuberculosis strains were isolated from new TB 
patients, implying ongoing transmission of MDR/XDR TB 
in Japan.
Our purpose was to evaluate the transmission dynam-
ics of MDR/XDR TB by using strains from the most recent 
(2002) nationwide drug-resistance survey in Japan, an in-
dustrialized country with low HIV incidence and interme-
diate TB incidence. We did so by analyzing the MDR/XDR 
strains by molecular genotyping methods, i.e., insertion 
sequence 6110 restriction fragment length polymorphism 
(IS6110-RFLP), spacer-oligonucleotide genotyping (spoli-
gotyping), and variable number tandem repeats (VNTR).
Materials and Methods
We used data and culture isolates obtained in the 2002 
nationwide drug-resistance survey, as previously reported 
(7). Brieﬂ  y, during June–November 2002, a total of 3,122 
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clinical strains were collected from different patients who 
had started treatment in 99 hospitals throughout Japan. 
The number of patients enrolled represented 36.0% of all 
new reported TB cases during the study period. The sam-
pling of the hospital was not randomized but was based on 
voluntary participation. The survey identiﬁ  ed 60 MDR/
XDR M. tuberculosis strains, 55 of which were analyzed 
in this study; the other 5 strains were unavailable for use 
in this study.
Patient Information
We used patient information collected from a standard 
data collection form in the drug-resistance survey in 2002 
(7). The information included demographic data (age, sex, 
nationality, hospital, geographic area of the hospital), clini-
cal data (history of TB treatment, site of TB disease, chest 
radiograph ﬁ  ndings, underlying disease), and bacteriologic 
data (results of sputum smear test for acid-fast bacilli). Pa-
tients were classiﬁ  ed as new if they had never been treated 
for TB for >4 weeks and as previously treated if they had 
ever been treated for TB for >4 weeks. The survey proto-
col conformed to the national guidelines for epidemiologic 
research (8).
Drug Susceptibility Testing
Drug susceptibility testing was performed at the Re-
search Institute of Tuberculosis, Tokyo, by using the pro-
portion method on standard 1% Ogawa egg-based slants 
(7) and the following drug concentrations: isoniazid 0.2 μg/
mL, rifampin 40 μg/mL, streptomycin 10 μg/mL, ethambu-
tol 2.5 μg/mL, ethionamide 20 μg/mL, kanamycin 20 μg/
mL, cycloserine 30 μg/mL, p-aminosalicylic acid 0.5 μg/
mL, and levoﬂ  oxacin 1 μg/mL. Pyrazinamide susceptibil-
ity was tested by using MGIT AST (Becton Dickinson, 
Sparks, MD, USA) at a concentration of 100 μg/mL. All 
compounds were obtained from Sigma (St. Louis, MO, 
USA).
Deﬁ  nition of XDR TB
We deﬁ  ned XDR strains according to the World Health 
Organization deﬁ  nition of XDR (1) and drug availability 
for TB treatment in Japan. XDR strains were deﬁ  ned as 
M. tuberculosis strains with resistance to at least isoniazid, 
rifampin, levoﬂ  oxacin, and kanamycin.
Molecular Genotyping 
Three molecular genotyping methods based on IS6110-
RFLP, spoligotyping, and VNTR were performed on the 55 
MDR/XDR strains. IS6110-RFLP typing was performed 
according to the standardized protocol (9). The RFLP band 
patterns were compared by using the BioNumerics software 
package version 5.1 (Applied Maths, Kortrijk, Belgium). 
Strains with an identical band pattern were classiﬁ  ed as an 
RFLP cluster. Spoligotyping was also performed according 
to the standard protocol (10). Classiﬁ  cation of the spoligo-
type family was performed according to the international 
database, SpolDB4 (11). The VNTR analysis was conduct-
ed as described elsewhere (12) by using the standard 15 
mycobacterial interspersed repetitive unit–VNTR proposed 
by Supply et al. (13), i.e., VNTRs 0424, 0577, 0580, 0802, 
0960, 1644, 1955, 2163b, 2165, 2401, 2996, 3192, 3690, 
4052, and 4156 plus 4 other loci, VNTRs 2074, 2372, 3155, 
and 3336. The latter 4 loci were added to increase discrimi-
nation for the Beijing family strains because of their high 
prevalence in Japan (12).
Statistical Analysis
Statistical analysis was performed with Epi Info soft-
ware 3.51 (Centers for Disease Control and Prevention, 
Atlanta, GA, USA), by using χ2 test or Fisher exact test 
for the comparison of proportions. A p value <0.05 was 
considered signiﬁ  cant.
Results
Epidemiologic Characteristics of Patients
A total of 55 MDR/XDR cases were analyzed. The 
characteristics of patients with MDR/XDR TB are sum-
marized and compared with those of patients with pansus-
ceptible strains (n = 2,782) in Table 1. Patients with MDR/
XDR TB were signiﬁ  cantly more likely to be younger (odds 
ratio [OR] 5.69 for age 21–40 years; 4.11 for age 41–60 
years) and foreigners (OR 6.41) and to have been previ-
ously treated (OR 10.55). All MDR/XDR TB patients had 
pulmonary disease, and these patients were signiﬁ  cantly 
more likely to have cavitary lesions (OR 3.24) and to have 
positive sputum smear test results (OR 2.20).
Of the 55 MDR/XDR TB cases, 17 (31%) were XDR 
TB. We found no signiﬁ  cant differences between patients 
with XDR TB and patients with MDR but not XDR (non–
XDR MDR) TB. XDR TB patients tended to be female, 
although the difference was not statistically signiﬁ  cant (p = 
0.06, Fisher exact test).
Analysis by Spoligotyping
We performed spoligotyping to determine the popula-
tion structure of the 55 MDR/XDR strains (Table 2). The 
most dominant spoligotype family in the MDR/XDR cases 
was the Beijing family genotype (62%, n = 34), followed 
by the T (13%, n = 7), Latino-American and Mediterranean 
(5%, n = 3), U (2%, n = 1), East-African Indian (2%, n = 
1), and X (2%, n = 1) family genotypes. Eight (15%) strains 
were unclassiﬁ  ed according to the database.
The proportion of the Beijing family, which is fre-
quently reported to be associated with drug resistance (14), 
did not signiﬁ  cantly differ between the non–XDR MDR M. 
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tuberculosis strains and XDR M. tuberculosis strains (68% 
vs. 47%; p = 0.14), and distribution of the other spoligotype 
families did not differ signiﬁ  cantly (data not shown).
Cluster Analysis by IS6110-RFLP
All 55 MDR/XDR strains were genotyped by IS6110-
RFLP, and 21 (38%) were classiﬁ  ed into 9 clusters, each 
with identical RFLP patterns (clusters 1–9) (online Ap-
pendix Figure, www.cdc.gov/EID/content/16/6/948-appF.
htm). All members of each cluster belonged to the same 
spoligotype family. The remaining 34 strains exhibited 
unique RFLP patterns. Cluster size ranged from 2 to 4, 
and 7 clusters had 2 members, 1 with 3 members and 1 
with 4 members. IS6110 copy numbers ranged from 1 to 
18. Four (7%) strains had <5 copies of IS6110, and these 
strains were discriminated as unique strains by the subse-
quent VNTR analysis. Of the 21 RFLP-clustered strains, 
13 (62%) were classiﬁ  ed as XDR M. tuberculosis, and 
8 (38%) were isolated from new TB patients. Of the 17 
XDR M. tuberculosis strains, 4 were resistant to all drugs 
tested, and 2 belonged to cluster 8. Among the 9 RFLP-
clusters, 7 were from Japanese patients exclusively; the 
other 2 clusters were from both Japanese and foreign-born 
patients.
Cluster Analysis by VNTR
The results of the 19-locus VNTR (15 mycobacterial 
interspersed repetitive unit–VNTR + additional 4 loci) 
analysis showed that 7 of the 9 RFLP-clusters were identi-
cal according to the 19-locus VNTR (online Appendix Fig-
ure). A difference in only 1 locus was observed in the re-
maining 2 RFLP-clusters: 1 at VNTR1955 in cluster 6, and 
1 at VNTR2163b in cluster 9 (online Appendix Figure).
Geographic Distribution of Hospitals with MDR/XDR 
TB Patients among Each Cluster
To estimate the possible clonal expansion of MDR/
XDR TB in communities, we compared the geographic ar-
eas of patients’ hospitals among each cluster (Table 3). The 
55 MDR/XDR TB patients were treated by 23 hospitals, 
which were located in 16 of the 47 prefectures in Japan. 
Of the 9 clusters, 7 consisted of patients whose hospitals 
were located in the same or neighboring prefectures, and 
the remaining 2 clusters consisted of patients whose hos-
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Table 1. Comparison of characteristics between TB patients with XDR TB and non-XDR MDR TB from the most recent (2002) 
nationwide drug susceptibility survey, Japan* 
Characteristic
No. (%) cases   Odds ratio (95% confidence interval) 
XDR,
n = 17 
Non–XDR
MDR, n = 38 
MDR/XDR,
n = 55 
Drug susceptible, 
n = 2,782 
MDR/XDR vs. drug 
susceptible 
XDR vs. non–XDR 
MDR 
Age, y 
  0–20  0 1 (3)  1 (2)  51 (2)  2.57 (–)  –
  21–40  6 (35)  14 (37)  20 (36)  460 (17)  5.69 (2.63–12.45) 0.51 (0.12–2.18) 
  41–60  10 (59)  12 (32)  22 (40)  701 (25)  4.11 (1.93–8.85) 1
>61 1 (6)  11 (29)  12 (22)  1,570 (56)  1 0.11 (0.00–1.11) 
Sex
  M  9 (53)  30 (79)  39 (71)  1,973 (71)  1 1
  F  8 (47)  8 (21)  16 (29)  809 (29)  1.00 (0.53–1.86)  3.33 (0.83–13.77) 
Nationality 
  Japanese  16 (94)  31 (82)  47 (85)  2,710 (97)  1 1
  Foreigner  1 (6)  7 (18)  8 (15)  72 (3)  6.41 (2.69–14.72) 0.28 (0.01–2.64) 
Treatment history 
  New  8 (47)  17 (45)  25 (45)  2,498 (90)  1 1
  Previous  9 (53)  21 (55)  30 (55)  284 (10)  10.55 (5.93–18.83) 0.91 (0.25–3.33) 
Site of TB 
  Pulmonary  17 (100)  38 (100)  55 (100)  2,687 (97)  – –
 Extrapulmonary  0 0 0 95  (3)  – –
Chest radiograph finding 
  Noncavitary  5 (29)  8 (21)  13 (24)  1,394 (50)  1 1
  Cavitary  12 (71)  30 (79)  42 (76)  1,388 (50)  3.24 (1.68–6.38) 0.64 (0.15–2.84) 
Sputum smear test result 
  Negative  3 (18)  6 (16)  9 (16)  838 (30)  1 1
  Positive  14 (82)  32 (84)  46 (84)  1,944 (70)  2.20 (1.03–4.85) 0.88 (0.16–5.23) 
Complication
  None  6 (35)  21 (55)  27 (49)  1,344 (48)  1 1
  Diabetes mellitus  4 (24)  7 (18)  11 (20)  438 (16)  1.25 (0.58–2.65)  2.00 (0.34–11.88) 
  Malignancy  3 (18)  2 (5)  5 (9)  180 (6)  1.38 (0.46–3.83)  5.25 (0.52–61.86) 
*TB, tuberculosis; XDR, extensively drug-resistant; MDR, multidrug-resistant; MDR/XDR, MDR TB and XDR TB; –, not available. Boldface indicates 
significance. MDR and XDR TB, Japan
pitals were located in the same region (i.e., a geographic 
and administrative area with several prefectures). Clus-
ters with geographic links suggest the clonal expansion of 
MDR/XDR TB occurred in local areas. Although patients 
in clusters 4 and 7 were from the same hospital, further 
information about their contact was unavailable because an 
epidemiologic survey was not performed.
Characteristics of Clustered Cases
We analyzed the associations of genetic clustering by 
IS6110-RFLP with patients’ characteristics and bacterio-
logic factors (Table 4). XDR TB occurred more frequently 
among the clustered cases than among the unique cases 
(OR 7.73), but differences between the 2 groups were not 
signiﬁ  cant for any of the remaining factors i.e., age, sex, 
nationality, treatment history, site of TB disease, chest ra-
diographic ﬁ  ndings, sputum-smear test results, underlying 
disease, or member of the Beijing family genotype.
Discussion
Our study described the transmission dynamics of 
MDR/XDR TB in Japan on a national scale. Analysis of the 
55 MDR/XDR TB cases showed that MDR/XDR TB was 
more frequent among younger patients, previously treated 
patients, and foreign-born patients than among patients with 
drug-susceptible TB (Table 1). In addition, the XDR TB 
cases, which represented 31% of the total MDR TB cases, 
were more likely to be associated with clustering than were 
the non–XDR MDR TB cases (Table 4), suggesting that 
ongoing transmission plays a critical role in new cases of 
XDR TB. We also found that the Beijing family genotype 
predominated in MDR/XDR M. tuberculosis (Table 2) and 
in drug-susceptible M. tuberculosis in this setting (12).
Although IS6110-RFLP analysis has been the standard 
for strain typing in studies of M. tuberculosis transmission, 
false clusters comprising strains without any epidemiolog-
ic link, and thus not reﬂ  ecting clonal transmission, have 
been reported (15–17). This use of IS6110-RFLP analy-
sis is especially problematic in area in which strains with 
stable RFLP patterns are endemic (18,19). In this context, 
because of its post hoc nature, a limitation of our study is 
its lack of information about epidemiologic links among 
clustered patients.
We therefore evaluated the genetic clonality of RFLP-
clustered strains more rigorously by using the 19-locus 
VNTR. Our previous study demonstrated that most of the 
RFLP-clustered strains without epidemiologic links were 
discriminated by the 19-locus VNTR (12). In this study, 
the results correlated strongly between RFLP and VNTR 
in terms of cluster formation; 7 of the 9 RFLP-clusters had 
completely identical 19-locus VNTR proﬁ  les (online Ap-
pendix Figure). Each of the remaining 2 clusters contained a 
single-locus variant, i.e., the difference was at only 1 locus of 
1 strain in each cluster. This minor difference in VNTR pro-
ﬁ  le is highly likely to have occurred as a random variation in 
strains from the same source, as argued by several investiga-
tors (13,20). In addition to analyzing by RFLP and VNTR, 
we conﬁ  rmed that all of the 9 clusters shared identical mu-
tations on drug resistance genes for rifampin and isoniazid 
(i.e., rpoB and katG, respectively, data not shown).
Geographic distribution of the hospitals also supports 
the clonal expansion of MDR/XDR TB (Table 3). Isolation 
of most of the clustered strains from hospitals in the same 
or neighboring prefectures may indicate that transmission is 
occurring in the communities. Furthermore, we assume that 
some of the clustering in our study did not result from direct 
transmission among the members but rather resulted from 
exposure of the members to a common infection source or 
infection with different sources sharing a near ancestor. The 
discordance of drug resistance other than isoniazid and ri-
fampin resistance among clusters implies that the stepwise 
acquisition of drug resistance had occurred chronologically 
during successive transmissions (online Appendix Figure). 
Thus, all these ﬁ  ndings support the assumption of ongoing 
community transmissions of MDR/XDR TB.
A high proportion (71%, 12/17) of the XDR strains 
were involved in clusters, a ﬁ  nding consistent with the re-
sults of a hospital-based study in Osaka, Japan (21). Of the 
12 clustered cases, 4 were new cases and 8 were among 
previously treated patients. The clustered XDR TB cases 
among the new cases strongly indicated that these persons 
had been primarily infected with XDR M. tuberculosis 
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Table 2. Distribution of Mycobacterium tuberculosis spoligotype families among 55 persons with MDR/XDR TB, Japan* 
Spoligotype family 
No. (%) cases 
XDR TB, n = 17  Non-XDR MDR TB, n = 38  MDR and XDR TB, n = 55 
Beijing†  8 (47)  26 (68)  34 (62) 
T 2 (12)  5 (13)  7 (13) 
LAM 3 (18)  0 3 (5) 
U 0 1 (3)  1 (2) 
EAI 0 1 (3)  1 (2) 
X 0 1 (3)  1 (2) 
Unclassified‡  4 (24)  4 (11)  8 (15) 
*MDR, multidrug-resistant; XDR, extensively drug-resistant; TB, tuberculosis; LAM, Latino-American and Mediterranean; EAI, East-African Indian. 
†Includes Beijing-like strains. 
‡Unclassified according to the SpolDB4. RESEARCH
strains. Also, TB may have developed in the clustered XDR 
TB patients with previous TB treatment as a result of exog-
enous reinfection with XDR TB, as described in a report of 
fatal TB in a patient infected with an MDR strain when his 
disease had been almost cured (22).
One possible explanation for the high clustering rate of 
XDR TB is that new cases of XDR TB are more likely to be 
caused by transmission than by acquisition of multiple drug 
resistance as a result of treatment failure. Shah et al. report-
ed that patients with XDR TB were more likely than those 
without XDR TB to be infectious in terms of duration and 
proportion of sputum smear positivity (3). Furthermore, at 
least 142 non–XDR MDR TB and 180 XDR TB patients 
were reported to be in Japan as of 2000 (23). All were cul-
ture positive, and a considerable number were treated as 
outpatients despite their infectiousness and drug resistance. 
Thus, we assume that some of those patients with chronic 
MDR/XDR TB may have played a role as a source of trans-
mission, as described in this study.
Because these ﬁ  ndings and our cluster analysis sug-
gest that the current TB control strategy is insufﬁ  cient to 
prevent community transmission of MDR/XDR TB, more 
detailed investigations of MDR/XDR TB transmission 
based on contact tracing are urgently needed to improve 
the infection control strategy, including an isolation policy 
for highly infectious patients with refractory drug-resistant 
strains. At the same time, ethical issues, such as the human 
rights of these patients, should be carefully considered.
Only a few cases of XDR TB transmission have ever 
been reported. A large group of XDR TB cases, mainly 
among HIV-infected patients, was reported in South Af-
rica (2). Another study in South Africa reported 12 cases 
of exogenous reinfection with XDR TB (24). In Iran, DNA 
ﬁ  ngerprinting analysis suggested 2 outbreaks of XDR TB 
involving 12 patients in 1 family and their close contacts 
(25). In Norway, a patient who was lost to follow-up has 
been transmitting an XDR M. tuberculosis strain for 12 
years, and that transmission has ultimately resulted in 15 
XDR TB cases (26). Consistent with these previous reports, 
our study has added novel evidence for clonal expansion 
of XDR M. tuberculosis strains even in an industrialized 
country with intermediate TB incidence and low incidence 
of HIV.
Another limitation of this study is a possible sampling 
bias, which could be caused by the following factors. First, 
the sampling of the survey participants was not random-
ized but was based on voluntary participation of the hos-
pitals, which may be likely to include more serious TB 
cases (7). Second, the sampling fraction is low (38%) and 
the study period is short (6 months), either of which may 
produce a biased subset of the total cases. In addition, the 
low sampling fraction and the short study period may lead 
to reduced clustering of cases (27,28). A more complete 
understanding of transmission dynamics of MDR/XDR TB 
requires a real-time DNA ﬁ  ngerprinting method such as 
VNTR on a nationwide scale.
Four strains from the 55 MDR/XDR TB cases were 
identiﬁ  ed as totally drug-resistant strains (29), indicating 
that they were resistant to all 10 drugs tested (online Appen-
dix Figure). Of these strains, 2 in 1 cluster (cluster 8) were 
from new cases, and both patients were women in their 20s 
who were full-time workers and had no underlying disease. 
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Table 3. Geographic distribution of hospitals among each cluster of MDR and XDR TB, Japan* 
Cluster no.  Patient ID  Type of TB  Hospital Geographic link of the hospitals in clusters 
1 DR43 MDR  A
DR42  XDR B A and B located in same prefecture 
2 DR14 MDR  C
DR53  MDR  D C located 103 km from D 
3 DR54 XDR D
DR58 XDR D
DR18  XDR E D and E located in same prefecture 
4 DR03 MDR  F
DR04 MDR  F Same hospital
5 DR11 MDR  G
DR10  MDR  H G located 221 km from H 
6 DR51 XDR D
DR50 XDR D
DR55 MDR  D
DR16  XDR E D and E located in same prefecture 
7 DR38 XDR D
DR39 MDR  D Same hospital
8 DR13 XDR I
DR56  XDR D I and D located in neighboring prefectures 
9 DR12 XDR I
DR49  XDR D I and D located in neighboring prefectures 
*MDR, multidrug-resistant; TB, tuberculosis; XDR, extensively drug-resistant. MDR and XDR TB, Japan
Both patients were registered in the same area (no further 
data available); TB as formidable as totally drug-resistant 
TB can affect otherwise healthy young adults even on a 
mass basis.
The results of this study showed that transmission of 
MDR TB, especially XDR TB, is currently occurring in 
communities of Japan. Further studies to prospectively 
identify the transmission route through contact tracing and 
real-time DNA ﬁ  ngerprinting methods on a population ba-
sis are required. Although the MDR/XDR TB problem is 
not great in Japan, our ﬁ  ndings highlight the relevance of 
proper infection control, as well as effective treatment, to 
further contain highly developed drug-resistant TB.
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